Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis
ConditionPsoriasis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorCentre Hospitalier Universitaire de Nice
About this trial
Dendritic cells (DC) paly a key role in the induction and chronicity of psoriasis by capturing the antigenes and activating the T cell repsonse. This activation requires their migration from the cutaneous sensitisation site to the lymph nodes. This migration requires an important intracellular metabolic activity, with a strong involvmenet of glucdic metabolism. This activity is linked with the systemic activity. This study aims to compare the migration and the phenotypic and metabolic caracteristics of blood and skin DCs in patients with or without psoriasis and with or without type 2 diabetes,
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients of both sexes
hospitalized in the Dermatology department of the CHU of Nice for moderate to severe psoriasis (defined by a PASI > or = 10)
covered by a social security scheme after obtaining a free
Clinical diagnosis of plaque psoriasis by a dermatologist with or without type 2 diabetes (defined by glycated hemoglobin >7%)
Disqualifiers
Minor or incapable or unwilling to consent freely or in an informed manner Pregnant or nursing woman.
Patient in a period of exclusion from other biomedical research
Patient with generalized chronic inflammatory disease or other inflammatory dermatosis
Patients on general corticosteroid, immunomodulator or immunosuppressant therapy in the month prior to local inclusion or treatment with corticosteroid therapy in the 15 days prior to inclusion, on anti- treatmentIL-23 or anti IL12/23 for less than 3 months or under anti-IL-17 or anti-TNF treatment for less than 1 month.
Trial design
Design model
Single group
Treatments tested in this trial
Biopsy and venous blood
Other interventionA skin biopsy will be performed under local anesthesia in diabetic and non-diabetic psoriatic patients (25 per group) in the injured area (joint extension) and in the non-injured area more than 2 cm from any lesion in the same area. In patients in the diabetic or non-diabetic control group (25 per group) only one biopsy will be performed. Peripheral venous blood will be collected in heparin tubes for metabolic parameter analysis and blood CD analysis
Treatment groups
100 Participants
are divided into 1 treatment groupGroup A: Production of IL-23 of blood and skin dendriti cells (CD)Other 1 intervention
Trial outcomes
Primary outcomes
1
Percentage of dentridic cells producers of IL-23
Alterations in the percentage of dentridic cells that have migrated with the metabolic status of patients
Time frame
at baselineSecondary outcomes
1
Percentage of subpopulations dentridic cells producers
Study of the percentage of the various cDC subpopulations according to the metabolic status of the patients.
Time frame
At baselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov